Professor of Clinical Immunology Toulouse University, France
Disclosure(s):
Roland Liblau, MD, PhD: Biogen: Consultant/Advisor (Terminated); GlaxoSmithKline: Grant Support (Terminated); Kite Pharma, Servier, Novartis: Consultant/Advisor (Ongoing), Lecture Fees (Ongoing); Merck: Consultant/Advisor (Ongoing), Lecture Fees (Ongoing); Orion: Consultant/Advisor (Terminated); Roche: Grant Support (Ongoing); Sanofi-Genzyme: Consultant/Advisor (Terminated)
Learning Objectives:
Upon completion, participants will be able to list the evidence pointing to the autoimmune origin of narcolepsy type 1.
Upon completion, participant will be able to understand the strenghts and limits of animal models.
Upon completion, participant will be able to define how genetic (HLA) and environmental (vaccine) factors may intersect in narcolepsy type 1 development.
